An update from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast Limited announced the appointment of Gregory George as a director, effective February 24, 2025. Gregory George holds significant interests in the company’s securities, including ordinary shares, warrants, and American Depositary Shares, which may influence the company’s strategic direction and stakeholder engagement.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on developing innovative cellular medicines. The company specializes in regenerative medicine products, primarily targeting conditions such as inflammatory diseases and cardiovascular disorders.
YTD Price Performance: 21.82%
Average Trading Volume: 279,088
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.15B
See more insights into MSB stock on TipRanks’ Stock Analysis page.